Custom Search

Tuesday, September 9, 2014

Sanofi pasteusr's Dengue Vaccine successful in Phase III trial

Dengue is life threatening disease as it causes sudden Dengue Vaccine successful in Phase III Clinical Trial in reducing instance of occurrence of dengue in 60.8% of subjects given dengue vaccine.
Dengue disease is caused by dengue fever virus, the Flavivirus infection and it is transmitted through mosquito bite. It tops the list of reason for loss of lives worldwide and it has very limited treatment options as well, which are limited to controlling symptoms of dengue fever, controlling fever, controlling its symptoms like headache and joint pain, which may extend to blood and platelet transfusion .

It becomes life threatening in event it cases low platelet count, resulting in to leakage of blood serum in to tissue, capillary eruption, and hemorrhagic conditions, which may lead to sudden shock.

There was no vaccine available to prevent dengue fever viral infection prior to its encounter, but now world is set to get one soon, on 3-Sep-2014 it was announced by Sanofi Pasteur's that a vaccine developed by Sanofi pasteusr a vaccine division of Sanofi, is successful in achieving clinical endpoint, in its phase 3 clinical trial, it is able to prevent dengue viral fever infection in about 60.8% of the total 20,875 children of age group 9 to 16 after giving them vaccine for three times, the clinical trial in an placebo controlled multicenter trial conducted in places or countries which are worst affected with dengue fever. The vaccine is successfully tested for its efficacy and safety against all four serotypes virus DENV-1, DENV-2, DENV-3 DENV-4.Moreover two pivotal clinical studies conducted involved 31000 subjects and vaccines immunogenicity was successfully evaluated.

Source: http://www.sanofipasteur.com/en/articles/sanofi-pasteur-s-dengue-vaccine-candidate-successfully-completes-final-landmark-phase-3-clinical-efficacy-study-in-latin-america.aspx

No comments:

Post a Comment

Enter your email address:

Enter your email address: